Gilead Sciences Inc (GILD)

GILD (NASDAQ:Drugs) EQUITY
$101.98
neg -1.40
-1.40%
Today's Range: 101.97 - 103.75 | GILD Avg Daily Volume: 16,294,200
Last Update: 03/06/15 - 12:27 PM EST
Volume: 3,836,614
YTD Performance: 9.71%
Open: $103.00
Previous Close: $103.42
52 Week Range: $63.50 - $116.83
Oustanding Shares: 1,489,401,683
Market Cap: 153,497,737,450
6-Month Chart
TheStreet Ratings Grade for GILD
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 13 11 11 13
Moderate Buy 2 2 2 2
Hold 3 3 3 3
Moderate Sell 1 1 1 0
Strong Sell 0 0 0 0
Mean Rec. 1.58 1.65 1.65 1.44
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 14.02
Price Earnings Comparisons:
GILD Sector Avg. S&P 500
14.02 14.00 27.74
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-1.12% 24.79% 347.39%
GROWTH 12 Mo 3 Yr CAGR
Revenue 122.20 1.97 0.43
Net Income 294.40 3.32 0.62
EPS 305.00 3.39 0.63
Earnings for GILD:
EBITDA 16.32B
Revenue 24.89B
Average Earnings Estimates
Qtr (03/15) Qtr (06/15) FY (12/15) FY (12/16)
Average Estimate $3.13 $2.76 $9.89 $9.39
Number of Analysts 1 1 2 2
High Estimate $3.13 $2.76 $10.64 $10.77
Low Estimate $3.13 $2.76 $9.13 $8.00
Prior Year $1.44 $2.32 $7.91 $9.89
Growth Rate (Year over Year) 117.36% 18.97% 24.97% -5.06%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
By

Jim Cramer

 | Mar 4, 2015 | 12:31 PM EST

Sector could regain its leadership role.

By

Bret Jensen

 | Mar 3, 2015 | 10:30 AM EST

This vaccine maker is now closer to several important milestones.

updateRBC Healthcare Conf.

Feb 25, 2015 | 7:13 AM EST

RBC Healthcare Conference

By

Jim Cramer

 | Feb 23, 2015 | 3:38 PM EST

Why does the market feel like it wants to roll over?

By

Doug Kass

 | Feb 23, 2015 | 8:51 AM EST
Deutsche Bank reiterates its Buy recommendation on Gilead (GILD) (price target $125) based on the company's exclusive agreement with AbbVie (ABBV) for its HCV drug.
By

David Katz

 | Feb 20, 2015 | 8:00 AM EST

JNJ provides low-risk, good income and modest appreciation.

By

Jim Cramer

 | Feb 19, 2015 | 11:02 AM EST

Watch this leadership group that's been lagging.

By

Bret Jensen

 | Feb 17, 2015 | 8:00 AM EST

They're in the tech, pharma and biotechnology sectors.

By

Jim Cramer

 | Feb 10, 2015 | 4:10 PM EST

Detached from overseas negatives, the market reacts rationally.

By

Timothy Collins

 | Feb 6, 2015 | 9:08 AM EST

But it doesn't bode well for the euro, Treasuries or metals.

Bonds and notes are taking it on the chin following a much better than expected jobs numbe...
if you wanted to counter Goldman's downgrade you could use the same line of reasoning that...
Two days ago, I noted that Weyerhaeuser (WY) had broken channel support, and yesterday com...
Where was Goldman Sachs when Lulu ran from the low 40s to the mid 60s? I believe they were...

REAL MONEY PRO'S BEST IDEAS

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.